Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development

Pediatrics

Volumn 121, Issue 4, 2008, Pages

  Shulman, Dorothy I ^a,e   Francis, Gary L ^b   Palmert, Mark R ^c   Eugster, Erica A ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

Author keywords

Aromatase inhibitors; Gynecomastia; Precocious puberty; Short stature

Indexed keywords

ALDOSTERONE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANDROSTANOLONE; ANDROSTENEDIONE; ANTIANDROGEN; AROMATASE INHIBITOR; BICALUTAMIDE; DESLORELIN; ESTRADIOL; FADROZOLE; FLUDROCORTISONE; FLUTAMIDE; FOLLITROPIN; FORMESTANE; GONADORELIN; GONADORELIN DERIVATIVE; GONADOTROPIN; GROWTH HORMONE; HYDROCORTISONE; LETROZOLE; LUTEINIZING HORMONE; PREDNISONE; SPIRONOLACTONE; TAMOXIFEN; TESTOLACTONE; TESTOSTERONE; TESTOSTERONE ENANTATE;

ABSENCE OF SIDE EFFECTS; ACNE; ADOLESCENT DEVELOPMENT; AGGRESSION; ALBRIGHT SYNDROME; ALDOSTERONE BLOOD LEVEL; ANDROGEN RELEASE; ANDROSTENEDIONE BLOOD LEVEL; BONE AGE; BONE DENSITY; BONE MATURATION; CHEMICAL STRUCTURE; CHILD DEVELOPMENT; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; FAMILIAL MALE PRECOCIOUS PUBERTY; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; GROWTH DISORDER; GROWTH RATE; GYNECOMASTIA; HORMONE SYNTHESIS; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MASTALGIA; OVARY CYST; PATIENT COMPLIANCE; PEUTZ JEGHERS SYNDROME; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; REVIEW; SERTOLI CELL TUMOR; SHORT STATURE; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VIRILIZATION; ADOLESCENT; AGE; BODY HEIGHT; BONE DEVELOPMENT; CHILD; DRUG EFFECT; FEMALE; MALE; PHYSIOLOGY; PRESCHOOL CHILD; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SEXUAL MATURATION;

ADOLESCENT; AGE FACTORS; AROMATASE INHIBITORS; BODY HEIGHT; BONE DENSITY; BONE DEVELOPMENT; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; FEMALE; GROWTH DISORDERS; GYNECOMASTIA; HUMANS; MALE; PROGNOSIS; PUBERTY, PRECOCIOUS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX FACTORS; SEXUAL MATURATION;

EID: 42949151943     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-2081     Document Type: Review

References (73)

1. Brodie AM, Banks PK, Inkster SE, Dowsett M, Coombes RC. Aromatase inhibitors and hormone dependent cancers. J Steroid Biochem Mol Biol. 1990;37(3):327-333
2. Bulun SE, Zeitoun K, Takayama K, et al. Estrogen production in endometriosis and use of aromatase inhibitors to treat en-dometriosis. Endocr Relat Cancer. 1999;6(2):293-301
3. Miller WR, Jackson J. The therapeutic potential of aromatase inhibitors. Expert Opin Investig Drugs. 2003;12(3):337-351
4. Dunkel L. Use of aromatase inhibitors to increase final height. Mol Cell Endocrinol. 2006;254-255:207-216
5. Plourde PV, Reiter EO, Jou H-C, et al. Members of the Asra-Zeneca Gynecomastia Study. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(9):4428-4433
6. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331(16):1056-1061
7. Morishima A, Grumbach M, Simpson E, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80(12):3689-3698
8. Cash R, Brough AJ, Cohen MN, Satoh PS. Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. J Clin Endocrinol Metab. 1967;27(9):1239-1248
9. Thompson EA Jr, Siiteri PK. The involvement of human placental microsomal cytochrome P-450 in aromatization. J Biol Chem. 1974;249(17):5373-5378
10. Geisler J, Lonning PE. Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005;11(8): 2809-2821
11. Cavalli A, Bisi A, Bertucci C, et al. Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005;48(23): 7282-7289
12. Numazawa M, Handa W, Hasegawa C, Takahashi M. Structure-activity relationships of 2 alpha-substituted androstenedi-one analogs as aromatase inhibitors and their aromatization reactions. J Steroid Biochem Mol Biol. 2005;97(4):353-359
13. Cavalieri E, Chakravarti D, Guttenplan J, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochem Biophys Acta. 2006;1766(1):63-78
14. Chen S, Zhang F, Sherman MA, et al. Structure-function studies of aromatase and its inhibitors: a progress report. J Steroid Biochem Mol Biol. 2003;86(3-5):231-237
15. Saberi MR, Vinh TK, Yee SW, Griffiths BJ, Evans PJ, Simons C. CYP19 (aromatase) 1-[(benzofuran-2-yl)(phenylmethyl) pyri-dine,-imidazole, and-triazole inhibitors: synthesis and biological evaluation. JMed Chem. 2006;49(3):1016-1022
16. Walgreens.com. Drug Information. Available at www. walgreens.com/library/ finddrug/druginfosearch.jsp. Accessed February 4, 2008.
17. Eugster EA. Aromatase inhibitors in precocious puberty: rationale and experience to date. Treat Endocrinol. 2004;3(3): 141-151
18. Geisler J, Lonning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol. 2005;95(1-5):75-81
19. Laue L, Kenigsberg D, Pescovitz OH, et al. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med. 1989;320(8):496-502
20. Laue L, Jones J, Barnes KM, Cutler GB Jr. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J Clin Endocrinol Metab. 1993;76(1):151-155
21. Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB Jr. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab. 1999;84(1):175-178
22. Reiter EO, Narjavaara E. Testotoxicosis: current viewpoint. Pediatr Endocrinol Rev. 2005;3(2):77-86
23. Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z. Treatment of familial male-limited precocious puberty with bicalutamide and anastrazole. J Pediatr. 2006;149(3):416-420
24. Feuillan PP, Foster CM, Pescovitz OH, et al. Treatment of precocious in the McCune-Albright syndrome with the aro-matase inhibitor testolactone. N Engl J Med. 1986;315(18):1115-1119
25. Feuillan PP, Jones J, Cutler GB Jr. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab. 1993;77(3): 647-651
26. Nunez SB, Calis K, Cutler GB Jr, Jones J, Feuillan PP. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab. 2003; 88(12):5730-5733
27. Roth C, Freiberg C, Zappel H, Albers N. Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15(suppl 3):945-948
28. th annual meeting of the Endocrine Society; June 19-20, 2003; Philadelphia, PA
29. Mieszczak J, Lowe E, Plourde P, Eugster EA. Anastrozole treatment of precocious puberty in girls with McCune-Albright syndrome [abstract 7517.7]. Presented at: annual meeting of the Pediatric Academic Society, May 3-8, 2007; Toronto, Ontario, Canada
30. Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab. 2007;92(6):2100-2106
31. Albers N, Jorgens S, Deiss D, Hauffa BP. McCune-Albright syndrome: the German experience. J Pediatr Endocrinol Metab. 2002;15(suppl 3):897-901
32. Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty. J Clin Endocrinol Metab. 2007;92(5):1635-1639
33. Silva IN, Kater CE, Cunha CF, Viana MB. Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Arch Dis Child. 1997;77(3):214-218
34. Eugster EA, Dimeglio LA, Wright JC, Freidenberg GR, Seshadri R, Pescovitz OH. Height outcome in congenital adrenal hyper-plasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr. 2001;138(1):26-32
35. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GB Jr. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2000;85(3):1114-1120
36. Braunstein G. Gynecomastia. N Engl J Med. 1993;328(7): 490-495
37. Harlan WR, Grillo GP, Cornoni-Huntley J, Leaverton PE. Secondary sex characteristics of boys 12 to 17 years of age: the U.S. Health Examination Survey. J Pediatr. 1979;95(2):293-297
38. Williams M. Gynecomastia: Its incidence, recognition and host characterization in 447 autopsy cases. Am J Med. 1963;34: 103-112
39. Nicolis GL, Modlinger RS, Gabrilove JL. A study of the histo-pathology of human gynecomastia. J Clin Endocrinol Metab. 1971;32(2):173-178
40. Bannayan GA, Hajdu SI. Gynecomastia: clinicopathologic study of 351 cases. Am J Clin Pathol. 1972;57(4):431-437
41. Nydick M, Bustos J, Dale JH Jr, Rawson RW. Gynecomastia in adolescent boys. JAMA. 1961;178:449-454
42. Plourde P, Julin H, Santner S. Clomiphene in the treatment of adolescent gynaecomastia. Am J Dis Child. 1983;137(11): 1080-1082
43. Konig R, Schonberger W, Neumann P, Benes P, Grimm W. Treatment of marked gyecomastia in puberty with tamoxifen [in German]. Klin Padiatr. 1987;199(6):389-391
44. Eberle A, Sparrow J, Keenan B. Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate. J Pediatr. 1986;109(1):144-149
45. Beck W, Stubbe P. Endocrinological studies of the hypo-thalamo-pituitary gonadal axis during danazol treatment in pubertal boys with marked gynecomastia. Horm Metab Res. 1982;14(12):653-657
46. Zachmann M, Eiholzer U, Muritano M, Werder EA, Manella B. Treatment of pubertal gynaecomastia with testolactone. Acta Endocrinol. 1986;279(suppl):218-226
47. Riepe FG, Baus I, Wiest S, Krone N, Sippell WG, Partsch CJ. Treatment of pubertal gynecomastia with the specific aro-matase inhibitor anastrozole. Horm Res. 2004;62(3):113-118
48. Klein KO, Baron J, Colli MJ, McDonnell DP, Cutler GB Jr. Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest. 1994;94(6):2475-2480
49. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol. 2005;23(4):808-815
50. Lefevre H, Bouvattier C, Lahlou N, Adamsbaum C, Bougneres P, Carel J-C. Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor. Eur J Endocrinol. 2006; 154(2):221-227
51. Kara C, Kutlu AO, Tosun MS, Apaydin S, Senel F. Sertoli cell tumor causing prepubertal gynecomastia in a boy with Peutz-Jeghers syndrome: the outcome of 1 year treatment with the aromatase inhibitor testolactone. Horm Res. 2005;63(5): 252-256
52. Shozu M, Sebastian S, Takayama K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med. 2003;348(19):1855-1865
53. Stratakis CA, Vottero A, Brodie A, et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab. 1998;83(4): 1348-1357
54. Leschek EW, Rose SR, Yanovski JA, et al. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(7): 3140-3148
55. Wit JM, Balen HV, Kamp GA, Oostdijk W. Benefit of postponing normal puberty for improving final height. Eur J Endocrinol. 2004;151(suppl 1):S41-S45
56. Pasquino AM, Pucarelli I, Roggini M, Segni M. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone. J Clin Endocrinol Metab. 2000;85(2):619-622
57. Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab. 1998;83(6): 1886-1892
58. Boot AM, Demuinck Keizer-Schrama SM, Pols HA, Drenning EP, Drop SL. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with precocious and early puberty. J Clin Endocrinol Metab. 1998;83(2):370-373
59. Yanovski JA, Rose SR, Municchi G, et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med. 2003;348(10):908-917
60. Faglia G, Arosio M, Porretti S. Delayed closure of epiphyseal cartilages induced by the aromatase inhibitor anastrozole: would it help short children grow up? J Endocrinol Invest. 2000;23(11):721-723
61. Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet. 2001;357(9270):1743-1748
62. Mauras N, WelchS, RiniA, KleinKO. Anopenlabel12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol Metab. 2004;17(12):1597-1606
63. Karmazin A, Moore WV, Popovic J, Jacobson JD. The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function. J Pediatr Endocrinol Metab. 2005;18(3):285-293
64. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab. 2005;90(12):6396-6402
65. Hero M, Wickman S, Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endo-crinol (Oxf). 2006;64(5):510-513
66. Cernich J, Jacobson JD, Moore WV, Popovic J. Use of aro-matase inhibitors in children with short stature. Pediatr Endo-crinol Rev. 2004;2(1):2-7
67. Turpin AL, Popovic J, Karmazin A, Moore WV, Jacobson JD.Aromatase inhibitor may delay skeletal maturation and improve final adult height in females [abstract]. 86th AnnualMeeting of the Endocrine Society, New Orleans, LA, June 16-19, 2004
68. Mauras N, Gonzalez de Pijem L, Hsiang H, et al. Placebo controlled, double blind, randomized trial of the safety and efficacy of Arimidex in delaying epiphyseal fusion in growth hormone (GH) deficient males in puberty: preliminary results [abstract]. 88th Annual Meeting of the Endocrine Society, Boston, MA, June 24-28, 2006
69. Front H, Lampit M, Hochberg Z. Aromatase inhibition therapy in pubertal short boys [abstract]. ESPE/LWPES Seventh Joint Meeting, Lyon, France, September 21-24, 2005
70. Carreau S, Delalande C, Silandre D, Bourquiba S, Lambard S. Aromatase and estrogen receptors in male reproduction. Mol Cell Endocrinol. 2006;246(1-2):65-68
71. Simpson ER. Genetic mutations resulting in estrogen insufficiency in the male. Mol Cell Endocrinol. 1998;145(1-2):55-59
72. Mauras N, Bell J, Snow BG, Winslow KL. Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: comparison with normal controls. Fer-til Steril. 2005;84(1):239-242
73. Hero M, Ankarberg-Lindgren C, Taskinen MR, Dunkel L. Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. Eur J Endocrinol. 2006;155(3):453-460